A Study of Melphalan in People with Lymphoma Getting an Autologous Stem Cell Transplant


Full Title

Pharmacokinetic Directed Melphalan for Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation


Autologous stem cell transplantation (ASCT) is a standard treatment for some people with lymphoma. It involves replacing the blood-forming cells that have been destroyed by disease, radiation, or high doses of anticancer drugs with healthy cells collected from a patient’s own blood.

To prepare the body for ASCT, doctors usually give a combination of four chemotherapy drugs called BEAM, one of which is melphalan. This standard chemotherapy can have side effects. In this study, researchers are assessing a new way of calculating the melphalan dose in BEAM that uses information based on people who have previously received melphalan. They believe that the melphalan dose calculated using this new method may still be effective but with fewer side effects than the standard dose of melphalan. Each patient will receive a dose of melphalan that is tailored to their personal needs.

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have Hodgkin lymphoma or non-Hodgkin lymphoma and be candidates for ASCT with BEAM.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people ages 18-79.


For more information and to ask about eligibility for this study, please contact the office of Dr. Parastoo Dahi at 646-608-3733.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID